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Objective: The introduction of drug-eluting stents (DES) has largely added benefit to the percutaneous coronary intervention.
Questions about the long-term safety of DES have been raised, however, particularly with respect to late stent thrombosis.
Research efforts are now being directed toward therapeutics that can impede smooth muscle proliferation and promote
vascular healing. Emerging data suggest that hemeoxygenase-1 (HO-1), an inducible oxidoreductase enzyme system, can exert
cytoprotective effects on endothelial cells and limit smoothmuscle cell proliferation.We assessed the ability of hemin, a potent
HO-1 inducer, to reduce in-stent stenosis without compromising re-endothelialization.
Methods:Rat aorta and rabbit iliac arteries were stented. Animals received ongoing treated with intraperitoneal hemin (50
mg/kg) or vehicle. At 7 to 28 days after surgery, stented arterial segments were collected and processed for histologic,
electron microscopy, or protein analysis.
Results: In bothmodels, treatment with hemin reduced neointima growthwithout compromising re-endothelialization of the
stented arteries. In the rat aorta, analysis of protein expression at 7 and 28 days after stenting revealed that hemin increased
HO-1 expression and limited the early inflammatory, apoptotic, and proliferative cellular events that are common to in-stent
stenosis. Hemin treatment decreased the expression of the Ki-67 protein and the activity of key regulators of smooth muscle
cell proliferation, including p42/44, RhoA, and up-regulated the expression of cyclin-dependent kinase inhibitors. The
beneficial effects of hemin were abolished in the presence of tin-protoporphyrin IX, an HO inhibitor. Finally, treatment with
tricarbonylchloro(glycinato)ruthenium(II), a carbon monoxide donor, reduced in-stent stenosis in the rat aorta, suggesting
that carbon monoxide, a by-product of heme degradation, might contribute to the protective effect of hemin.
Conclusion: These results suggest that HO-1 is important in limiting in-stent stenosis and can be regarded as a new
therapeutic target. ( J Vasc Surg 2010;51:417-28.)
Clinical Relevance: Long-term outcomes of endovascular treatments have not been impressive due to vascular stenosis
caused mainly by intimal hyperplasia. Questions have been raised about the long-term safety of drug-eluting stents,
particularly with respect to late stent thrombosis. Accumulating data indicate a link between inflammation and in-stent
stenosis as well as between delayed endothelialization and thrombosis. We demonstrated in an animal model that hemin,
a compound used in the management of porphyria, induced heme oxygenase-1 and limited inflammation and in-stent
restenosis without compromising endothelialization. Thus, heme oxygenase-1 may be considered as a novel target in the
next generation of drug-eluting stents for preventing in-stent restenosis after endovascular therapies.From the Laboratoire de Physiopathologie de la Paroi Artérielle, EA3852,
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doi:10.1016/j.jvs.2009.09.004Recurrent stenosis remains the major drawback of percuta-
neous transluminal angioplasty. In percutaneous coronary
intervention (PCI), stenting provides an added benefit by
reducing the risk of reocclusion.1 However, the major
adverse event occurring with the use of stent devices is
in-stent stenosis (ISS),2 which is considered a local vascular
response to injury. Endothelial injury produces elements of
thrombus formation, and fibrin and platelet deposition
stimulate inflammatory aggregates. The subsequent pro-
duction of adhesion molecules, cytokines, and growth fac-
tor by the platelets, inflammatory cells, and smooth muscle
cells leads to an enhanced inflammatory reaction, apoptosis,
and smooth muscle proliferation.
Anticoagulant and antiplatelet therapies have to an
extent succeeded in reducing the complications of throm-
bosis. Furthermore, with the advent of drug-eluting stents
(DESs) that can deliver antiproliferative drugs, it has been
anticipated that by reducing stenosis, DESs may improve
the long-term prognosis of patients treated with these
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gioplasty has increased progressively, and by 2004, DESs
were used in 80% of all PCIs.
Although the short-term tomidterm beneficial effect of
DESs has been recognized in coronary vessels, recent long-
term meta-analyses of DESs have raised questions about
their long-term safety, particularly with respect to late stent
thrombosis. Poor long-term effects of DESs may arise from
the nonselective inhibition of endothelial cell proliferation
by the antiproliferative drugs, which could result in delayed
and incomplete re-endothelialization as well as incomplete
healing of the stented vessels.5,6 Finally, the use of DESs for
noncoronary applications is still investigational, and long-
term follow-up results are needed to determine the superi-
ority of DESs.7
Research efforts are now being directed toward thera-
peutics that can impede smooth muscle proliferation and
promote vascular healing. Heme oxygenase-1 (HO-1) is
the rate-limiting enzyme in heme degradation that leads to
the generation of free iron, biliverdin, and carbon monox-
ide (CO). Accumulated evidence suggests that HO-1 offers
protection against several cardiovascular disorders.8 We
recently observed that hemin, a potent HO-1 inducer,
prevented arterial thrombosis.9 The induction of HO-1 has
been shown to prevent the proliferation of smooth muscle
cells and to promote the growth of endothelial cells in
vitro.10,11 Increased HO-1 expression is associated with
decreased intimal thickening after balloon injury.12-14
However, percutaneous coronary angioplasty is widely as-
sociated with stent insertion, thus stenosis therapies must
include stenting of vessels.
Taken together, these reports suggest that induction of
HO-1 might limit ISS without compromising vessel heal-
ing. Among in vivo models of ISS, stenting of the rat aorta
has been shown to be a reliable and reproducible model of
ISS that, in contrast with other species, enables the inves-
tigation of cellular mechanisms.15
This study assessed the potential protective effects of
hemin against the development of ISS in rat and in hyper-
cholesterolemic rabbit models. In particular, we wanted to
test the hypothesis that hemin treatment and the delivery of
CO, a by-product of heme degradation by HO-1, would
limit excessive neointima formation and allow the endothe-
lialization of the stent struts after stent implantation.
MATERIALS AND METHODS
All animal experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
(US National Institutes of Health publication 85-23, re-
vised 1996), in accordance with the regulations of the
official edict of the French Ministry of Agriculture, and
were approved by local Institutional Animal Care and Use
Committee (CL2008-015 and CL2008-028). All surgical
procedures were performed by a single operator.
Ratmodel of in-stent stenosis. MaleWistar rats (Jan-
vier, Le Gesnest-Saint-Isles, France), weighing 350 to
400 g, were randomly separated into control or drug-
treated groups. On day 0, the rats were anesthetized andthe abdomen was opened by a sagittal incision. Under
microscopic view, the abdominal aorta was separated from
the vena cava, and small side branches from the aorta were
ligated. An arteriotomy was made in the proximal part of
the 2.5 cm-long isolated infrarenal aortic segment. Then, a
premounted stent bare-metal stent (BMS), 2.5  14 to 18
mm, or a sirolimus DES, 2.5 14mm (Cordis, Johnson &
Johnson, Miami, Fla) was deployed at its nominal pressure
(8 atm).
At 7 and 28 days after stenting, the animals were
anesthetized, heparinized, and blood was collected.
Stented arteries were perfused with fixative for histologic
and electron microscopy analysis (on day 28) or frozen for
protein expression analysis (on days 7 and 28).
Rats implanted with BMSs received vehicle, intraperi-
toneal (IP) hemin (50 mg/kg), tin-protoporphyrin IX
(SnPPIX; 15 mg/kg), a potent inhibitor of HO16; SnPPIX
plus hemin (50 mg/kg each), or CORM-3 (tricarbonyl-
chloro(glycinato)ruthenium[II]; 30 mg/kg), a water solu-
ble CO-releasing molecule.17 On the basis of preliminary
experiments, drugs were administered every 48 hours start-
ing 2 days before surgery. Rats implanted with sirolimus-
DESs received saline.
For each series of experiments, different control and
drug-treated rats were used and distributed as indicated in
the flow chart (Fig 1, A). Stent length was homogenous
between the different groups to avoid bias.
Hypercholesterolemic rabbit model of ISS. Male
New Zealand White rabbits (3.5 to 4.0 kg; INRA, Nouz-
illy, France) received a hypercholesterolemic diet (standard
diet supplemented with 1% cholesterol) starting 4 weeks
before surgery and maintained throughout the duration of
the experimental protocol. On day 0, the animals were
anesthetized and the right common carotid artery was
catheterized with a 5F introducer sheath. A 0.035-inch
guidewire was used to position a 4F diagnostic catheter in
the abdominal aorta under fluoroscopic observation. The
iliac arteries were catheterized using a 0.014-inch guide-
wire, and premounted stents (3.0 10 to 24-mm balloon-
expandable BMS or sirolimus-DES; Cordis) were deployed
at their nominal pressure (8 atm) in each iliac artery under
fluoroscopic guidance. The stent-to-artery ratio was over-
sized (ratio 1.2:1.0).
After stent implantation, vessel patency was docu-
mented with angiography. At 28 days after stent implanta-
tion, a second angiography was performed under general
anesthesia, followed by euthanasia and perfusion-fixation.
The stented arteries were collected and processed for his-
tologic or electron microscopic analysis. Control rabbits
received vehicle (saline, IP), and the hemin-treated rabbits
received hemin (50 mg/kg, IP) every 48 hours, starting 2
days before surgery. In the control group, three rabbits
were implanted with a sirolimus-DES in one iliac artery (Fig
1, B). Stent length was homogenous between the different
groups to avoid bias.
Serum cholesterol levels in the control and hemin-
treated rabbits were, respectively, 391  20 and 381  36
tting
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and 640  38 mg/dL on day 28 (P  .05).
Histologic analysis. Stented arteries were fixed in
4% paraformaldehyde phosphate-buffered solution, dehy-
drated, and embedded in methylmethacrylate polymer
(Technovit 9100 new, Heraeus, Germany). Embedded
vessels were cut along the entire stented length. Sections
(60-m thick) were stained with Mayer hematoxylin and
eosin and viewed under light microscopy. From each
stented vessel, 15 to 25 sections randomly chosen along the
entire stented length were analyzed by computer-based
image analysis using Optimas 6.5 software (Media Cyber-
netics, Silver Spring, Md). The degree of in-stent stenosis
was derived from the ratio of the area of neointima to that
of the media (n/m ratio), and the statistical analysis was
conducted on the average of all sections per stent. Because
measurements were made by a single operator who was
Fig 1. Study flow chart for (A) rat model and (B) hyperc
(tricarbonylchloro(glycinato)ruthenium[II]; DES, siroli
microscopy; SnPP, tin-protoporphyrin; WB, Western bloblinded to the treatments, we used the standard deviationderived from the average of all sections per stent as an index
of the variability of stenosis within each stent.
Electron microscopy. Stented arteries were fixed in
4% paraformaldehyde and 1% glutaraldehyde phosphate-
buffered solution (pH 7.2). Then they were cut longitudi-
nally, and one-half was used for transmission electron mi-
croscopy (TEM) and the other half for scanning electron
microscopy (SEM).
For TEM, samples were embedded in Epon. Ultrathin
sections (75 nm) were processed and contrasted with ura-
nyl acetate and lead citrate and examined through a Jeol
1011 electron microscope (Tokyo, Japan) equipped with a
Gatan digital camera driven byDigitalMicrograph software
(Gatan, Pleasanton, Calif).
For immunogold labeling, ultrathin sections were incu-
bated with antiplatelet endothelial cell adhesion molecule-1
goat polyclonal antibody (SantaCruz Biotechnology Inc,
teremic rabbit model. BMS,Bare-metal stent;CORM-3,
rug-eluting stent; EM, electron microscopy; LM, light
.holes
mus dSanta Cruz, Calif) and then incubated with a secondary
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noglobulin (Ig) G (Electron Microscopy Science, Eurome-
dex, France). For each stented segment, three stent struts
with surrounding neointima were randomly chosen.
For SEM, the samples were processed and coated by
platinum sputtering (5 nm) and observed using a LEO
DSM 982 SEM (Zeiss, Germany). The coverage of stented
vessel was analyzed over the entire surface of the specimen.
Hemin plasmatic assay and bilirubin assay. The
plasma concentrations of heme were determined using
the pyridine-hemochromogen method, as previously de-
scribed.9 Quantitative determination of bilirubin pro-
duction was determined from the plasma of rats using the
Quantichrom Bilirubin Assay kit (Bioassay Systems, Gen-
taur, France). Briefly, total bilirubin was assayed from 200
L of plasma using the Jendrassik-Grof method accord-
ing to the manufacturer’s instructions.
Protein expression. Protein expression was deter-
mined in the stented rat aorta at 7 and 28 days after stent
deployment. Stented aortic segments were placed in lysis
buffer, and the stent was carefully removed under optical
control. The primary antibodies used were anti-HO-1,
anti-p42/44 mitogen-activated protein kinase (MAPK),
antiphosphorylated p42/44 MAPK, anti-p27kip1 (Ozyme,
France), anti-Ki67, anti-p21 (SantaCruz Biotechnology
Inc, France), anti-RhoA (Upstate, France) and antiactin
(Sigma-Aldrich, France). The secondary antibodies were
antirabbit IgG, antimouse IgG, or antigoat horseradish
peroxidase-conjugated (Ozyme). Bound antibodies were
visualized by enhanced chemiluminescence (ECL; Amer-
sham Biosciences) and quantified by densitometric analysis
(NIH Image analysis software).
Cytokines arraywas performed according to themanufac-
turer’s instruction. Briefly, equal amount of proteins (300g)
were incubated with a detection antibody cocktail for 1 hour
at room temperature. Then each sample/antibodies mixture
was incubated with a nitrocellulose membrane with spotted
antibodies and incubated 2 hours at6°C (Proteome Profiler
Rat Cytokine Array, R&D Systems, France). Bound antibod-
ies were visualized by ECL and quantified by densitometric
analysis.
Statistical analysis. Data were reported as mean 
standard error of the mean, and n refers to the number of
stented arteries from which the analysis was performed. For
histologic data, we used an unpaired t test to compare
means for control and hemin groups. For electron micros-
copy and Western blot analysis, comparisons of means
between the control and hemin groups were performed
using an unpaired t test. Values of P .05 were considered
statistically significant.
RESULTS
Effect of hemin treatment on in-stent stenosis in rat
and rabbit models. In control rats, a concentric neoin-
tima was observed 28 days after stenting. The ratio of the
area of neointima to the area of media (n/m ratio) was
0.83  0.06 (n  8; Fig 2, A). In rats that were implantedwith a sirolimus-DES, neointima was almost absent
(n/m 0.45 0.03, n 3), and the stent struts remained in
contact with the lumen. In hemin-treated rats, the n/m
ratio was decreased by 30% compared with the control
group (0.57  0.03, n  8, P  .01), and the stent struts
remained covered by a thin layer of cells (Fig 2, A). Fur-
thermore, the variability of the stenosis within each arterial
segment was lowered in hemin-treated rats (Fig 2, A). In
this group, the plasma hemin concentration was 32  3
mol/L.
At 28 days after stent deployment, angiography of the
aortoiliac bifurcation revealed stenosis in four to seven
hypercholesterolemic control rabbits (Fig 2, B); this was
not observed in the hemin-treated rabbits. Histologic anal-
ysis of the stented arteries (Fig 2, B) revealed that n/m ratio
was 0.90  0.05, which was decreased in hemin-treated
rabbits (48%, P .001, n 8) compared with 1.72 0.10
in the controls (n  7). Similarly, the variability of the
stenosis along the stented vessels was reduced in the hemin
group (Fig 2, B).
Effect of hemin treatment on endothelialization of
stented vessels in rat and rabbit models. In the stented
rat aorta at 28 days after stenting, TEM analysis revealed a
thinner neointima covering the stent struts in the hemin-
treated group compared with the control animals (n  8
each; Fig 3, A), which is in agreement with the histologic
analysis. The ultrastructure of the cells facing the arterial
lumen was similar to that of endothelial cells (Fig 3, A).
Immunogold labeling of CD31, an endothelial marker, was
positive on these cells (Fig 3, B). SEM analysis showed that
the endothelial coverage area was similar in both control
and hemin-treated rats (Fig 3, C).
In the hypercholesterolemic rabbits, TEM revealed
similar results to those observed in the rats (Fig 3, D). In
addition, SEM analysis showed similar endothelialization
28 days after surgery in controls and hemin-treated rabbits
(n  4 each, Fig 3, E).
Effects of hemin treatment on protein expression in
rat. Because the inflammatory response is an early event
after stent deployment, we assessed the levels of various
cytokines and inflammatory adhesion molecules in stented
aortic segments at 7 days after stent deployment. A protein
array revealed a significant decrease of several immunogenic
and chemoattractant cytokines such as interleukin 6 and
tumor necrosis factor- as well as adhesive molecules such
as intercellular adhesion molecule 1 in the hemin-treated
rats (n 4) compared with the control group (n 4 each,
P  .05; Fig 4, A).
At 7 days after stent deployment, HO-1 expression was
significantly increased in hemin-treated rat aortas com-
pared with controls (n  5 each, P  .01), indicating that
the hemin treatment was sufficient to induce HO-1 protein
(Fig 4, B and C). Western blotting showed that the level of
cleaved caspase 3 was markedly attenuated in the hemin-
treated rats (P  .01), indicating reduced apoptotic re-
sponse. In hemin-treated aortas, Ki-67 expression was sig-
nificantly decreased, indicating reduced proliferation of the
vascular cells (Fig 4, C).
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Fig 2. Effect of hemin treatmenton in-stent stenosis is shown in rats andhypercholesterolemic rabbits.A,Rat aortamorphology
28 days after stenting. The bar graph shows the n/m ratio in control (n 8), hemin-treated (n 8), and aortas stented with
sirolimusdrug-elutingstents (DES,n3).Thescattergraph indicates the standarddeviation (SD)of then/mratioofeachstented
aortic segment from control and hemin-treated rats. SDwas derived from the average of the 15 to 25 analyzed sections per stent
andused as an index of the variability of stenosiswithin each stent.B,Angiography of the rabbit aortoiliac bifurcation28days after
stent deployment is shown in the top panel. The insert shows higher magnification of the red box. The daggers indicate stenosis.
The morphology of the iliac stented arteries (red box) is presented in the bottom panel. The bar graph shows the n/m ratio in
control (n7), hemin-treated (n8), and sirolimus-DES stented iliac arteries (n3).The results are themean standard error
of themean. The scatter graph indicates the SD of the n/m ratio of each stented iliac arteries. Significant difference from control:
*P .05, **P .005.
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February 2010422 Hyvelin et alFig 3. A,Transmission electronmicroscopic (TEM) analysis of the endothelialization of stented arteries is shows neointima (n)
around the stent strut (s) in the control and hemin-treated rats (original magnification875).Highermagnification (5000) of
the cells at the interfaceof the lumen(L) showsultrastructure similar to thatof endothelial cells.Thearrows indicate tight junctions.
B, Immunogold labeling of CD31 on cells facing the arterial lumen in hemin-treated rats. The top panel shows neointima above
stent strut.Highermagnification of the black box is presented below and shows positive labeling ofCD31on the selected cell. The
schematic diagram shows a two-dimensional reconstruction of the selected cell from five consecutive ultrathin sections. C,
Scanning electron microscopy (SEM) shows endothelial coverage of the stented aorta. The inserts show SEM at a lower
magnificationof the stented arteries. Thebar graph shows themean endothelial coverage in the control andhemin-treated groups
(n 8 per group). The error bars show the standard error of themean.D,TEM shows the neointima (n) around the stent strut
(s) in rabbit iliac arteries. The inserts showSEMat a lowermagnification of the stented arteries. The bar graph indicates neointima
thickness above the stent struts (n  4 in each groups). The error bars show the standard error of the mean.
**Significantly different from control (P  .005). E, SEM shows endothelial coverage of the stented iliac artery.
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Volume 51, Number 2 Hyvelin et al 423Fig 4. Effect of hemin treatment on protein expression in rat aortas 7 days after stenting. A, Protein array of
inflammatory cytokines in control (n  4) and hemin-treated (n  4) rats. The results are the mean  standard error
of the mean. B, Typical Western blot of proteins from stented aortas of control and hemin-treated rats. Each lane
represents one rat. C, Protein levels were quantified by densitometry and normalized with respect to -actin. Activities
of p42/44 and RhoA were expressed as the ratio of phosphorylated p42/44 to total p42/44 and the ratio of guanosine
triphosphate (GTP)-bound RhoA to total RhoA, respectively. The results are the mean  standard error of the mean
(n  5 each group). Significant difference from control: *P  .05, **P  .005. HO-1, heme oxygenase-1; IL,
interleukin; INF, interferon-; IP-10, interferon-inducible protein 10; MIP, macrophage inflammatory protein;
RANTES, regulated upon activation normal T-cell expressed and secreted; sICAM, soluble intercellular adhesion
molecule 1; TNF, tumor necrosis factor.
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cell proliferation. Hemin treatment resulted in significantly
increased expression of cyclin-dependent kinase inhibitors
p21 and p27kip1, supporting reduced proliferation of vas-
cular cells (Fig 4,C). Finally, we examined the expression of
RhoA and p42/44 MAPK, two proteins that are known to
participate in cell proliferation, migration, and differentia-
tion. The RhoA-activated form, guanosine triphosphate
(GTP)-bound RhoA, and the expression level of phosphor-
ylated p42/44 were significantly reduced in hemin-treated
rats.
Interestingly, we further assessed the effect of hemin on
these molecules at day 28 (Fig 5). As expected, HO-1
expression remained higher in hemin-treated rats com-
pared with the controls (n 5 each; Fig 5, B). As previously
observed, the protein Ki-67 remained higher (P  .05) in
the hemin-treated group, although the difference was less
than that at day 7 (Fig 5, C). Regarding the regulators of
cell cycle, p21 (P  .05) and p27kip1 (P  .05) remained
up-regulated and GTP-RhoA and phosphorylated p42/44
both remained down-regulated (P  .05) in the hemin-
treated rats (Fig 5, C).
Effect of SnPPIX in a rat model of in-stent stenosis.
To ensure that the protective effects of hemin relied specif-
ically on HO-1, we performed additional experiments to
test the effect of SnPPIX, a potent competitive inhibitor of
HO. In rats treated (28 days) with IP SnPPIX (50 mg/kg)
plus hemin (50 mg/kg) for 48 hours, histologic analysis
showed that the n/m ratio was increased by 20% (n  5,
P  .01) compared with the control groups (Fig 6, A).
Similarly, long-term treatment with SnPPIX alone in-
creased the n/m ratio by 19% compared with the controls
(n  5 each, Fig 6, A). To confirm the inhibitory effect of
SnPPIX on HO-1 activity, we assessed plasma bilirubin
level. In both the SnPPIX and SnPPIX plus hemin groups,
plasma bilirubin levels were similar to those observed in
control rats and were significantly lowered compared with
the hemin group (Fig 6, A).
Effect of CORM-3 in rat model of in-stent stenosis.
Because heme catabolism leads to CO production, we
tested the effect of CORM-3, a specific COdonor in ISS. In
rats treated with IP CORM-3 (30 mg/kg), the n/m ratio
measured at 28 days was significantly less than that in the
control rats (0.58  0.01 vs 0.70  0.02, n  5 each, P 
.001; Fig 6,A). This effect of CORM-3was independent of
HO-1 activity, as indicated by the plasma bilirubin level
(Fig 6, A).
DISCUSSION
Despite the beneficial effects of DESs in reducing the
incidence of ISS, concerns have been raised about the
associated risk of late stent thrombosis due to the cytostatic
and cytotoxic effects on endothelialization of the coated
drugs.5 The results of the present study show that hemin, a
potent HO-1 inducer, limited ISS without compromising
the endothelialization of the stented arteries in both rat and
hypercholesterolemic rabbit models of ISS.Long-term hemin treatment reduced ISS in the stented
rat aortas by 31% and by 48% in the rabbit iliac arteries, a
classically usedmodel to test antistenosis therapies.18 Inter-
estingly, in both hemin-treated rats and rabbits, the BMS
struts remained covered. This is the most powerful surro-
gate indicator of endothelialization and is in contrast to
aorta and iliac arteries stented with sirolimus DESs. It is
noteworthy that proper healing of stented vessels requires
re-endothelialization to limit smooth muscle prolifera-
tion and also to ensure proper hemostatic properties.
Re-endothelialization of hemin-treated rat aorta and rabbit
iliac artery was further supported by electron microscopy
analysis and was similar in the control and hemin-treated
groups. This effect is in agreement with the multifaceted
effects of hemin, which are cell type-specific. Hemin has
been reported to limit the proliferation of vascular smooth
muscle cells and to promote the proliferation of endothelial
cells in vitro.10,11,19
Using the rat aorta stenting model, we further investi-
gated the cellular mechanisms underlying the protective
effect of hemin. Inflammatory responses and apoptosis have
been recognized to be involved in the early events of
stenosis.20-22 We observed that hemin prevented early in-
flammatory response, in agreement with its well known
anti-inflammatory effect.23 In addition, apoptosis response,
assessed by the level of cleaved caspase 3, the end effector of
cellular apoptosis, was decreased by 80% after hemin treat-
ment. The reduced apoptosis suggests that the reduced
thickness of the neointima was due to reduced prolifera-
tion.
In this regard we obtained several lines of evidence of
the early antiproliferative effect of hemin. First, the expres-
sion of Ki-67, a protein strictly associated with cell prolif-
eration, was significantly lowered in hemin-treated rats.
Furthermore the expression of p21 and p27kip1 proteins,
two cyclin-dependent kinase inhibitors,24 was higher. Sec-
ond, the level of activated p42/44 and activated RhoA, two
regulators of proliferation, migration, and differentiation of
the smooth muscle cells,25,26 were decreased in hemin-
treated rats. The antiproliferative effects were maintained
for a longer period (up to 28 days). A similar antiprolifera-
tive effect of hemin was reported in animal model of angio-
plasty.13,14
Our observations, however, extend the previous find-
ings in two important ways. First, long-term treatment with
hemin limits inflammatory response and apoptosis in an in
vivo model of stent-induced vascular injury and limits vas-
cular smooth muscle cell proliferation. Second, to the best
of our knowledge, this is the first time that the antiprolif-
erative effects of hemin have been linked to decreased
activity of RhoA and increased expression of both p21 and
p27kip1. Further studies of messenger RNA (mRNA) ex-
pression could provide greater insight in the time-course of
gene expression during restenosis and in the cellular mech-
anisms involved in the protective effect of hemin.
In the present study we assessed the expression of
proteins at day 7 and day 28, which is within a time frame
that allows protein up-regulation or down-regulation. Fur-
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Volume 51, Number 2 Hyvelin et al 425Fig 5. Effect of hemin treatment on protein expression is shown in rat aortas 28 days after stenting. A, In this typical
Western blot of proteins from stented aortas of control and hemin-treated rats, each lane represents one rat.
B, Densitometry analysis shows heme oxygenase-1 (HO-1) expression and cleaved caspase 3. C, Protein levels are
shown for the regulators of cell proliferation. The upper panel shows the expression of the Ki-67 protein, assessed by
Western blot analysis (left) and immunofluorescence (right). Immunofluorescence shows better expression of the
Ki-67 protein in the control group. Negative controls are presented below. The lower panel shows the expression of
the p21, p27kip1, p42/44, and RhoA. The results are the mean standard error of the mean of five rats in each group.
Significant difference from control: *P  .05, **P  .005. GTP, Guanosine triphosphate.
d err
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useless regarding the effect of hemin treatment on the
activation of the proteins such as p42/44, RhoA, and
caspase 3, which relies on phosphorylation, GTP binding,
or cleavage.
Having established that hemin induced HO-1 expres-
sion and limited ISS, we wanted to verify that this effect
relied on the HO-1 activity. In presence of SnPPIX, a










































Fig 6. Effect of chronic treatment with tin-protop
ruthenium(II) (CORM-3) on in-stent stenosis in rat aort
SnPPIX (15 mg/kg), SnPPIX plus hemin (50 mg/kg, ea
graph represents mean n/m  standard error of the m
presented below. Significant difference from control: *P
in-stent stenosis in rat aortas and rabbit iliac arteries. Resu
with control groups. The results are the mean  standarpotent HO-1 inhibitor, hemin no longer had an effect, asindicated by the increased stenosis (20%). SnPPIX alone
worsened stenosis, suggesting that endogenous HO might
also limit ISS. In this regard, recent studies demonstrated a
greater occurrence of in-stent coronary stenosis associated
with a ho-1 gene promoter polymorphism,27,28 although
another report cast doubt on this association.29
We further assessed the activity of HO-1 by measuring






















yrin IX (SnPPIX) and tricarbonylchloro(glycinato)-
Aorta morphology 28 days after stenting in the control,
nd CORM-3 rats (30 mg/kg; n 5 all groups). The bar
The plasma bilirubin levels in the different groups are
, **P .005).B, Effect of pharmacologic treatments on
expressed as percentage change of n/mwhen compared






lts arebilirubin. With blood gas analysis we failed to detect any
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plasma bilirubin production was increased in hemin-treated
rats and lowered in the presence of SnPPIX. These data
further supported the conclusion that increased HO-1
activity limited ISS.
CO and bilirubin have both been proposed to exert
protective actions on the cardiovascular system.30 Interest-
ingly, the levels of bilirubin in the groups of rats treated
with SnPPIX were similar to those in control rats, despite
higher stenosis. Therefore, a byproduct of heme catabo-
lism, possibly CO, might afford protection against ISS.
This conclusion was reinforced by the decreased n/m ratio
in CORM-3-treated rats, in agreement with the anti-
inflammatory, antiproliferative, and antiapoptotic effects of
both CO gas and CORMs.17,31-34 Thus, in our model, it is
conceivable that the hemin-afforded protection relies on
both CO and bilirubin.
This study has some limitations. First, in the rat model
of in-stent stenosis, the neointima hyperplasia is very low
compared with the well-established porcine coronary artery
and rabbit iliac artery models. Although the low n/m ratio
weakens this animal model, we observed a reliable and
reproducible n/m ratio among the different control rats.
Most importantly, after sirolimus-DES deployment, the
n/m ratio was significantly decreased by 55%. Thus in the
rat abdominal stenting model, the n/m ratio is robust and
significant enough to assess the effect of drug therapy that
can reduce in-stent stenosis.
Second, hemin treatment was initiated 48 hours before
stenting. This delay was necessary to increase HO-1 after the
IP injection of hemin. However, such approach would not
be compatible with an emergency clinical situation such as
acute ST elongation myocardial infarction, It remains to be
determined if local delivery of hemin orCO, or both, through
the means of release platforms (suchmetallic or bioresorbable
DESs) would allow faster up-regulation of HO-1. In this
regard it is noteworthy that in cultured smooth muscle cells,
hemin induced HO-1 up-regulation4 hours.10,35 Further-
more, local delivery should be likely important to avoid any
potential systemic side effect.
Third, the protective effect of hemin against ISS will
require long-term follow-up to determine (1) if the protec-
tion is maintained at later time points (3 to 6 months) and
(2) if there is any rebound in inflammatory and proliferative
response when hemin treatment is stopped.
Finally, we observed that the decreased n/m was less in
hemin-treated rats than that in aortas stented with sirolimus
DESs. However, sirolimus inhibits mammalian target of
rapamycin C1 and C2 and ultimately increases the cyclin-
dependent kinases (CKDs) inhibitors in endothelial cells
and impairs their viability and function,36 whereas HO-1
exerts cytoprotective effects on endothelial cells and in-
creases their proliferation through the down-regulation of
cyclin-dependent kinases.37
CONCLUSIONS
Despite these limitations, the present study shows that
hemin induced HO-1 expression and reduced in-stent ste-nosis in rat and hypercholesterolemic rabbit models. Cellu-
lar analysis revealed that hemin limited the early inflamma-
tory response, apoptosis, and the proliferation of vascular
cells. Most importantly, hemin did not alter the healing and
re-endothelialization of the stented arteries, which con-
trasts with the findings obtained with the classic sirolimus
DES. Therefore, HO-1 activation appears to be important
in limiting ISS and can be regarded as new therapeutic
target.
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